SEQTOR trial shows comparable PFS for STZ/5-FU followed by everolimus and the reverse sequence in advanced pancreatic NETs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results